Randomized trial · people
PT-141: more responders than placebo at 1.75 mg on all 7 measures
Checked against the paper Randomized trialPublished by PepVault
The takeaway
This paper set the bar for what counts as a real response to bremelanotide in women with low desire, found the 1.75 mg dose cleared it more often than placebo, and supplied the response definitions later used in the RECONNECT phase 3 studies.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2019
- Journal
- J Sex Med
What they tested
The team wanted to set the smallest change in sexual function scores that patients would find meaningful, then use that cutoff to see how many women responded to bremelanotide (PT-141) versus placebo.
How the study was done
A randomized, placebo-controlled, dose-finding phase 2b trial in premenopausal women with hypoactive sexual desire disorder (HSDD, low sexual desire), with or without female sexual arousal disorder (FSAD). Seven questionnaire-based endpoints were checked with up to 4 kinds of responder analysis, some planned and some post hoc (decided after the data came in).

What they found
Cutoffs for a meaningful change, worked out from the trial's own data, lined up with the cutoffs clinical experts had estimated. On all 7 endpoints, the 1.75 mg arm had a statistically significant higher share of responders than placebo in the main analysis group. The team reported bremelanotide was safe and well tolerated in this trial.
What it doesn’t show
Only premenopausal women diagnosed with HSDD and/or FSAD were studied, so the results may not apply to other people. The meaningful-change cutoffs came from the same trial they were used to judge, and some of the analyses were post hoc.
The paper
Althof et al. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. J Sex Med. 2019.
The compound
More studies on PT-141
- PT-141: side-effect dropouts far higher than placebo in re-analysisMeta-analysis · people · 2021
- PT-141: desire gains over placebo held across RECONNECT subgroupsRandomized trial · people · 2022
- PT-141 with alcohol was well tolerated in 24 healthy adultsRandomized trial · people · 2017
- PT-141: +0.7 vs +0.2 satisfying sexual events a month at 12 weeksRandomized trial · people · 2016
- PT-141: nausea in 40.0% vs 1.3% on placebo in phase 3 safety dataSystematic review · people · 2022
- Every study on PT-141
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.